Opus Genetics announced FDA alignment on the Phase 3 registrational trial design for OPGx-LCA5 in treating inherited retinal dystrophy (Type B Rare Dis). The regulatory agreement is a positive de-risking step for the company’s late-stage program, though no efficacy/safety or timeline update was provided in the excerpt.
Opus Genetics announced FDA alignment on the Phase 3 registrational trial design for OPGx-LCA5 in treating inherited retinal dystrophy (Type B Rare Dis). The regulatory agreement is a positive de-risking step for the company’s late-stage program, though no efficacy/safety or timeline update was provided in the excerpt.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
